PepGen Reports 46.5% Splicing Correction in DM1 Trial

PepGen's 10 mg/kg cohort achieved 46.5% mean splicing correction. Results from the fully enrolled 12.5 mg/kg cohort are due in 2027, while $104.8 million supports operations into 2028.